PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
October 18, 2012Circulation Heart Failure212 citationsOpen Access

Comorbidity and Ventricular and Vascular Structure and Function in Heart Failure With Preserved Ejection Fraction

View Full Paper
SMSelma F. MohammedBBBarry A. BorlaugVRVéronique L. Roger

Key Result

HFpEF was consistently associated with greater concentric hypertrophy, atrial enlargement, and systolic, diastolic, and vascular dysfunction compared with healthy and hypertensive controls.

Study Design

Type

Cohort (n=965)

Structured PICO

P
Population
965 individuals from community-based cohorts, comprising patients with heart failure and preserved ejection fraction (HFpEF) (n=386), age/sex-matched healthy controls (n=193), and hypertensive controls (n=386).
C
Comparator
Age/sex-matched healthy controls (n=193) and hypertensive controls (n=386)
O
Outcome
Comorbidity-adjusted cardiovascular structural and functional parameterssurrogate

HFpEF is characterized by fundamental disease-specific changes in cardiovascular structure and function that are independent of common comorbidities, supporting the search for mechanistically targeted therapies.

Abstract

BACKGROUND: Patients with heart failure and preserved ejection fraction (HFpEF) display increased adiposity and multiple comorbidities, factors that in themselves may influence cardiovascular structure and function. This has sparked debate as to whether HFpEF represents a distinct disease or an amalgamation of comorbidities. We hypothesized that fundamental cardiovascular structural and functional alterations are characteristic of HFpEF, even after accounting for body size and comorbidities. METHODS AND RESULTS: Comorbidity-adjusted cardiovascular structural and functional parameters scaled to independently generated and age-appropriate allometric powers were compared in community-based cohorts of HFpEF patients (n=386) and age/sex-matched healthy n=193 and hypertensive, n=386 controls. Within HFpEF patients, body size and concomitant comorbidity-adjusted cardiovascular structural and functional parameters and survival were compared in those with and without individual comorbidities. Among HFpEF patients, comorbidities (obesity, anemia, diabetes mellitus, and renal dysfunction) were each associated with unique clinical, structural, functional, and prognostic profiles. However, after accounting for age, sex, body size, and comorbidities, greater concentric hypertrophy, atrial enlargement and systolic, diastolic, and vascular dysfunction were consistently observed in HFpEF compared with age/sex-matched normotensive and hypertensive. CONCLUSIONS: Comorbidities influence ventricular-vascular properties and outcomes in HFpEF, yet fundamental disease-specific changes in cardiovascular structure and function underlie this disorder. These data support the search for mechanistically targeted therapies in this disease.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Mohammed et al. (2012) conducted a cohort in Heart Failure With Preserved Ejection Fraction (n=965). Heart failure with preserved ejection fraction (HFpEF) vs. Age/sex-matched healthy and hypertensive controls was evaluated on Cardiovascular structural and functional parameters. HFpEF was consistently associated with greater concentric hypertrophy, atrial enlargement, and systolic, diastolic, and vascular dysfunction compared with healthy and hypertensive controls.

synapsesocial.com/papers/6a0ef576a14f152feafa132dhttps://doi.org/10.1161/circheartfailure.112.968594
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Obesity and heart failure prognosis: paradox or reverse epidemiology?2004 · 127 citations
  2. 2Burden of Systolic and Diastolic Ventricular Dysfunction in the Community2003 · 3,008 citations
  3. 3Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme2008 · 714 citations
  4. 4Effective arterial elastance as index of arterial vascular load in humans.1992 · 834 citations
  5. 5Diastolic Stiffness of the Failing Diabetic Heart2007 · 735 citations